(b)(2) or not to be, that is the question
USFDA 505(b)(2) pathway submissions (“(b)(2)s”) can be advantageous because they…
Nanoform at CPHI Barcelona 2023 – Chemicals Knowledge Hub Interview
In this interview filmed at CPHI Barcelona, Nanoform CCO Christian…
Future-proofing drug development with nanoparticle engineering
Nanoparticle formulations are a key tool for addressing drug development…
How Nanoform is Shaping a Greener Future for Pharma
In order to truly benefit patients and the world, it…
Feeling the Pressure: Polymorphism, Particle Size and Morphology Control Through Nanoparticle Crystallization Using Controlled Expansion of Supercritical Solutions
Our talented team presented their research at AAPS PharmSci 360…
Nanoform: small is green: utilizing innovative nanoparticle technologies To build a more sustainable pharmaceutical value chain
How can nanoparticle engineering build a more sustainable pharmaceutical value…
Feeling the pressure: nanoparticle crystallization using controlled expansion of supercritical solutions
Nanoforming improves bioavailabiliy by increasing the specific surface area of…
Characterization of the Flux Performance of Nanoformed and Untreated Crystalline Piroxicam Solid Suspensions, and the Relative Contributions of the Particle Drifting Effect to In Vitro Flux.
Presented at the 2023 Controlled Release Society Annual Meeting by…